LPCN
Lipocine Inc.
Biotechnology
Market Cap$13M
5Y Perf.-90.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LPCN vs NUVB
Revenue, margins, valuation, and 5-year total return — side by side.
NUVB
Nuvation Bio Inc.
Biotechnology
Market Cap$1.67B
5Y Perf.-51.8%
LPCN vs NUVB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LPCN | NUVB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $13M | $1.67B |
| Revenue (TTM) | $2M | $143M |
| Net Income (TTM) | $-11M | $-146M |
| Gross Margin | -13.4% | 91.6% |
| Operating Margin | -413.6% | -105.0% |
| Total Debt | $0.00 | $10M |
| Cash & Equiv. | $5M | $164M |
LPCN vs NUVB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LPCN
NUVB
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 100 | 9.5 | -90.5% |
| Nuvation Bio Inc. (NUVB) | 100 | 48.2 | -51.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LPCN vs NUVB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVB leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Lipocine Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LPCN
Lipocine Inc.
The Income Pick
LPCN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.86
- Lower volatility, beta 0.86, current ratio 6.68x
- Beta 0.86, current ratio 6.68x
Best for: income & stability and sleep-well-at-night
NUVB
Nuvation Bio Inc.
The Growth Play
NUVB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 7.0%, EPS growth 71.6%
- -51.8% 10Y total return vs LPCN's -98.4%
- 7.0% revenue growth vs LPCN's -82.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVB | 7.0% revenue growth vs LPCN's -82.3% |
| Quality / Margins | NUVB | -102.1% margin vs LPCN's -5.7% |
| Stability / Safety | LPCN | Beta 0.86 vs NUVB's 2.04 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NUVB | +136.3% vs LPCN's -27.6% |
| Efficiency (ROA) | NUVB | -23.8% ROA vs LPCN's -59.4%, ROIC -54.3% vs -64.7% |
LPCN vs NUVB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
LPCN vs NUVB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVBLAGGINGLPCN
LPCNLipocine Inc.
1leads
NUVBNuvation Bio Inc.
3leads
6 Total Categories
CATEGORYLEADERvs LPCNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVB6/6
Valuation MetricsMultiples, price ratios, and targets
LPCN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUVB6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVB6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVB leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NUVB is the larger business by revenue, generating $143M annually — 71.4x LPCN's $2M. Profitability is closely matched — net margins range from -102.1% (NUVB) to -5.7% (LPCN).
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| RevenueTrailing 12 months | $2M | $143M |
| EBITDAEarnings before interest/tax | -$8M | -$145M |
| Net IncomeAfter-tax profit | -$11M | -$146M |
| Free Cash FlowCash after capex | -$8M | -$126M |
| Gross MarginGross profit ÷ Revenue | -13.4% | +91.6% |
| Operating MarginEBIT ÷ Revenue | -4.1% | -105.0% |
| Net MarginNet income ÷ Revenue | -5.7% | -102.1% |
| FCF MarginFCF ÷ Revenue | -3.9% | -88.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.2% | +26.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -54.3% | +106.3% |
NUVB leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
LPCN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| Market CapShares × price | $13M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $8M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.41x | -8.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.58x | 26.61x |
| Price / BookPrice ÷ Book value/share | 0.94x | 5.38x |
| Price / FCFMarket cap ÷ FCF | — | — |
LPCN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
NUVB leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
NUVB delivers a -44.1% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-67 for LPCN. On the Piotroski fundamental quality scale (0–9), NUVB scores 4/9 vs LPCN's 0/9, reflecting mixed financial health.
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -66.7% | -44.1% |
| ROA (TTM)Return on assets | -59.4% | -23.8% |
| ROICReturn on invested capital | -64.7% | -54.3% |
| ROCEReturn on capital employed | -58.5% | -42.8% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 4 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$5M | -$154M |
| Cash & Equiv.Liquid assets | $5M | $164M |
| Total DebtShort + long-term debt | $0 | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | -162.11x |
NUVB leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
NUVB leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVB five years ago would be worth $4,173 today (with dividends reinvested), compared to $1,011 for LPCN. Over the past 12 months, NUVB leads with a +136.3% total return vs LPCN's -27.6%. The 3-year compound annual growth rate (CAGR) favors NUVB at 43.8% vs LPCN's -16.7% — a key indicator of consistent wealth creation.
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -70.1% | -43.8% |
| 1-Year ReturnPast 12 months | -27.6% | +136.3% |
| 3-Year ReturnCumulative with dividends | -42.1% | +197.5% |
| 5-Year ReturnCumulative with dividends | -89.9% | -58.3% |
| 10-Year ReturnCumulative with dividends | -98.4% | -51.8% |
| CAGR (3Y)Annualised 3-year return | -16.7% | +43.8% |
NUVB leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LPCN and NUVB each lead in 1 of 2 comparable metrics.
Risk & Volatility
LPCN is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVB currently trades 49.4% from its 52-week high vs LPCN's 19.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 2.04x |
| 52-Week HighHighest price in past year | $12.37 | $9.75 |
| 52-Week LowLowest price in past year | $1.81 | $1.57 |
| % of 52W HighCurrent price vs 52-week peak | +19.3% | +49.4% |
| RSI (14)Momentum oscillator 0–100 | 34.1 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 463K | 4.3M |
Evenly matched — LPCN and NUVB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LPCNLipocine Inc. | NUVBNuvation Bio Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $12.40 |
| # AnalystsCovering analysts | — | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LPCN leads in 1 (Valuation Metrics). 1 tied.
Best OverallNuvation Bio Inc. (NUVB)Leads 3 of 6 categories
Loading custom metrics...
LPCN vs NUVB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LPCN or NUVB a better buy right now?
For growth investors, Nuvation Bio Inc.
(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -82. 3% for Lipocine Inc. (LPCN). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LPCN or NUVB?
Over the past 5 years, Nuvation Bio Inc.
(NUVB) delivered a total return of -58. 3%, compared to -89. 9% for Lipocine Inc. (LPCN). Over 10 years, the gap is even starker: NUVB returned -51. 8% versus LPCN's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LPCN or NUVB?
By beta (market sensitivity over 5 years), Lipocine Inc.
(LPCN) is the lower-risk stock at 0. 86β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 137% more volatile than LPCN relative to the S&P 500.
04Which is growing faster — LPCN or NUVB?
By revenue growth (latest reported year), Nuvation Bio Inc.
(NUVB) is pulling ahead at 699. 0% versus -82. 3% for Lipocine Inc. (LPCN). Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LPCN or NUVB?
Nuvation Bio Inc.
(NUVB) is the more profitable company, earning -325. 3% net margin versus -487. 1% for Lipocine Inc. — meaning it keeps -325. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUVB leads at -338. 7% versus -524. 7% for LPCN. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LPCN or NUVB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LPCN or NUVB better for a retirement portfolio?
For long-horizon retirement investors, Lipocine Inc.
(LPCN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LPCN: -98. 4%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LPCN and NUVB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LPCN is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(LPCN: 27.2% · NUVB: 2598.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.